The European Commission (EC) has authorised Apretude (cabotegravir long-acting [LA] injectable and tablets) for HIV prevention. Cabotegravir injection is indicated in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in high-risk adults and adolescents (at least 12 years of age), weighing at least 35 kg. The availability of cabotegravir LA for PrEP will differ from country to country across the EU. ViiV Healthcare are committed to working with respective regulatory authorities, governments, payors and other stakeholders to understand the local needs and make this product available to people who can benefit from this innovative prevention option.